Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Abstract: Disclosed are: a virus vector in which a gene encoding an antigenic polypeptide is integrated in human parainfluenza virus type 2 gene, wherein the antigenic polypeptide is expressed in the form of a fusion protein with a viral structural protein; and a method for producing the same. The virus vector of the present invention contains a quantitatively large amount of the antigenic peptide on the virus particle and can efficiently deliver the antigenic polypeptide to a target cell.

Abstract: A lithium air battery including an electrolyte including lithium ion conductive polymers and lithium salts between a positive electrode and a lithium ion conductive solid electrolyte membrane. The lithium ion conductive polymers are hydrophilic matrix polymers.

Abstract: The present invention aims at providing a novel indocyanine compound solving problems of conventionally used indocyanine green, such as solubility in water or physiological saline, a synthesis method and a purification method thereof, and a diagnostic composition including the novel indocyanine compound. Further, provided are a method for evaluating biokinetics of the novel indocyanine compound and a device for measuring biokinetics, and a method and a device for visualizing circulation of fluid such as blood in a living body, which utilize the diagnostic composition. Also, found are a novel indocyanine compound in which a hydrophobic moiety in a near-infrared fluorescent indocyanine molecule is included in a cavity of a cyclic sugar chain cyclodextrin to cover the hydrophobic moiety in the indocyanine molecule with the glucose, and a synthesis method and a purification method thereof.

Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Abstract: A substrate having an annealed AlN layer includes a substrate made of a material selected from among a group including sapphire, silicon carbide (SiC), and aluminum nitride (AlN), and an aluminum nitride (AlN) layer formed on the substrate and having a thickness of 100 nm or greater. The aluminum nitride layer is annealed at a prescribed annealing temperature and in a nitrogen/carbon monoxide (N2/CO) mixed gas atmosphere, and the nitrogen/carbon monoxide (N2/CO) mixed gas has a mixture ratio of N2 gas/CO gas in a range of 0.95/0.05 to 0.4/0.6.

Abstract: Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.

Abstract: A substrate having an annealed AlN layer includes a substrate made of a material selected from among a group including sapphire, silicon carbide (SiC), and aluminum nitride (AlN), and an aluminum nitride (AlN) layer formed on the substrate and having a thickness of 100 nm or greater. The aluminum nitride layer is annealed at a prescribed annealing temperature and in a nitrogen/carbon monoxide (N2/CO) mixed gas atmosphere, and the nitrogen/carbon monoxide (N2/CO) mixed gas has a mixture ratio of N2 gas/CO gas in a range of 0.95/0.05 to 0.4/0.6.

Abstract: [Problem] To provide a curable composition having high stability and excellent curing properties. [Solution] The present invention relates to a curable composition, and a cured synthetic resin using same, that functions as a curing catalyst for a synthetic resin. The curable composition contains (A) a titanium alkoxide, (B) a bidentate organic chelating agent that stabilizes the titanium alkoxide and (C) a guanidine compound. The molar ratio of the titanium alkoxide (A), the bidentate organic chelating agent (B), and the guanidine compound (C) is 1:0.5-3:0.5-2.

Abstract: Provided is an antibody production method whereby it is possible to repeatedly acquire antibodies produced by fish without killing the fish. Specifically provided is an antibody production method whereby it is possible to repeatedly acquire the antibodies produced by a fish, without killing the fish, by administering antigens to fish that have blisters.

Abstract: A lithium ion secondary battery is provided, including: a positive electrode and a negative electrode into which, and from which, lithium ions can be introduced and be discharged reversibly, and an electrolyte membrane placed therebetween, wherein the electrolyte membrane is obtained using an electrolyte made by blending (A) a polyanion type lithium salt, (B) a boron compound, and (C) an organic solvent.

Abstract: Provided is a rapid and simple method of detecting methylated DNA. The method of detecting methylated DNA includes the following steps of: (1) treating sample DNA with a hydrogen sulfite; (2) amplifying the sample DNA treated with the hydrogen sulfite by PCR; and (3) subjecting the resultant PCR amplification product to ion-exchange chromatography.

Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Abstract: A protected anode for lithium air batteries and a lithium air battery including the protected anode are provided. The protected anode includes: an anode intercalates and deintercalates lithium ions; a lithium ion-conductive solid electrolyte membrane; and a polymer electrolyte disposed between the anode and the ion-conductive solid electrolyte membrane, wherein the polymer electrolyte includes a lithium ion-conductive polymer, a compound represented by Formula 1 having a number average molecular weight from about 300 to about 1,000, and a lithium salt, and an amount of the compound of Formula 1 is from about 10 parts to about 25 parts by weight based on 100 parts by weight of the polymer electrolyte: In Formula 1, R1 to R6, and n are the same as defined in the specification.

Abstract: Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.

Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Abstract: The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.

Abstract: A protected anode including an anode including a lithium titanium oxide; and a protective layer including a compound represented by Formula 1 below, a lithium air battery including the same, and an all-solid battery including the protected anode: Li1+XMXA2?XSiYP3?YO12??<Formula 1> wherein M may be at least one of aluminum (Al), iron (Fe), indium (In), scandium (Sc), or chromium (Cr), A may be at least one of germanium (Ge), tin (Sn), hafnium (Hf), and zirconium (Zr), 0?X?1, and 0?Y?1.

Abstract: Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.

Abstract: A lithium air battery including: a negative electrode including lithium; a positive electrode using oxygen as a positive active material; and an organic electrolyte, wherein the organic electrolyte includes a metal-ligand complex.